In a large cohort of de novo AML patients, DNMT3A mutations commonly co-occurred with NPM1, FLT3-ITD, IDH1/2, and FLT3-TKD mutations (Torabi et al., 2022). This evidence concerns the gene IDH1 and acute myeloid leukemia.